Pediatric Rheumatologist|Vasculitis Research Fellow @SickKids|Offspring of @canna_lab and @ChildrensPgh| PhD candidate @DrRaeYeung @UofTIMS #rheumtwitter
Toronto, Canada
Joined April 2011
- Tweets26
- Following459
- Followers228
- Likes283
Paul Tsoukas retweeted
Looking forward to hosting our international community from May 5th - 7th! #CABC2024
We are in the final week of preparation for the @CAFsociety Family day on Sunday and then the @cabc2024 conference! Looking forward to sharing findings from our @ucancandu health economics research, seeing colleagues and our JIA PaCERS! #cabc2024 #connectingJA
Paul Tsoukas retweeted
Hey @Penn_IFI @PennBiology @IGGPenn! We're looking for a new tech for this summer to (try to) fill @DangitVinh's enormous shoes😭. Promising Penn senior could get a jumpstart by joining now. We study inflammation, especially IL-18 but lesser cytokines too. DM or email!
Paul Tsoukas retweeted
New @CDCMMWR on Multisystem Inflammatory Syndrome (MIS-C), due to COVID, in children, ages 12-18.
*Pfizer's vaccine was 91% effective against MIS-C
*Among critically ill MIS-C patients requiring life support, all were unvaccinated.
cdc.gov/mmwr/volumes/71/wr/m…
Paul Tsoukas retweeted
New Research: Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis – Two Ends of the Same Spectrum: Kawasaki disease (KD) and systemic juvenile idiopathic arthritis (sJIA) are two distinct systemic inflammatory diseases of childhood.… frontiersin.org/articles/10.… #Pediatrics
Paul Tsoukas retweeted
1/ People say #MISC is not #KawasakiDisease. Okay. But what if Kawasaki disease took an s, one per virus, and MIS-C were one of many Kawasaki diseases & if MIS-C were a consequence of inborn errors of immunity (IEI) to SARS-CoV-2, different from those underlying C-19 pneumonia?
Paul Tsoukas retweeted
RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis ow.ly/IU0p50Es1aO
Paul Tsoukas retweeted
Hey #CIS2021, if you love IL-18 and cytotoxicity as much as we do, you needn't wait until Thursday to see our own Emily Landy's talk. cdmcd.co/nQRbqZ CISAM21
Paul Tsoukas retweeted
New Research: VISTA: A Target to Manage the Innate Cytokine Storm: In recent years, the success of immunotherapy targeting immunoregulatory receptors (immune checkpoints) in cancer have generated enthusiastic support to target these receptors… frontiersin.org/articles/10.… #immunology
Paul Tsoukas retweeted
Are you a healthcare professional who has been inspired by #RareDiseaseDay to learn more about #autoinflammation? Check out the newly launched #OneInAMillionPodcast hosted by @m_batthish us18.campaign-archive.com/?e…
Paul Tsoukas retweeted
We will be live @CHOP_Research/@Penn_IFI on 4/1 & hope to recruit a post-doc who will thrive in a spectacular translational immunology environment studying #IL18, #autoinflammation, #HLH, #MAS. Experience w CRISPR screens, live-cell 🔬 a +. DM or email if interested. Kindly RT.
Paul Tsoukas retweeted
Excited to share this preprint: Distinct Inflammatory Biomarker Patterns in COVID-19 Associated MIS-C Suggest Overlap between Kawasaki Disease and Macrophage Activation Syndrome @SSRN papers.ssrn.com/sol3/papers.…
Paul Tsoukas retweeted
Today is #RareDiseaseDay🗓️1 in 12 Canadians are affected by a rare disorder. CORD is a proud supporter of the @rarediseaseday! #RareDiseaseDay21 #Awareness #Canada4Rare
Paul Tsoukas retweeted
Chronic high #IL18 = risk of Macrophage Activation Syndrome, right? Enter PSTPIP1. "Excess Serum IL-18 Distinguishes Patients with Pathogenic Mutations in PSTPIP1" doi.org/10.1101/2021.02.22.2…
Paul Tsoukas retweeted
The major changes from V1:
1. Inclusion of steroids as first-line option, even for mild MIS-C
2. LD-ASA for all MIS-C pts, unless plt <80k
2. Removal of toci recommendation for COVID-associated hyperinflammation
Summary: rheumatology.org/Portals/0/F…
Dx and Tx algorithms 👇
Just accepted in Arthritis & Rheumatology:
American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 2.
onlinelibrary.wiley.com/doi/…
Paul Tsoukas retweeted
And for the #pediatric rheumatologists, we have a #YearinReview on immune profiling in MIS-C
#COVID19 #rheumatology
Read it for #free here go.nature.com/2KoX3dE
